Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 136,942 Shares

Key Points

• Roivant Sciences insider Mayukh Sukhatme sold 136,942 shares at an average price of $36.73, generating approximately $5.03 million. He still directly owns 18.63 million shares, following additional sales totaling more than $19.1 million earlier in August.
• ROIV shares rose 3.1% to $37.37, near the company’s 52-week high, while its latest quarterly loss of $0.26 per share beat analyst expectations but revenue came in below estimates.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and several firms raising price targets to $41–$42. Institutional investors own approximately 64.76% of the company.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 136,942 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66. Following the completion of the sale, the insider directly owned 18,630,739 shares in the company, valued at $684,307,043.47. This represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75.

Roivant Sciences Stock Up 3.1%

Shares of Roivant Sciences stock traded up $1.13 during midday trading on Tuesday, hitting $37.37. The company's stock had a trading volume of 6,409,504 shares, compared to its average volume of 5,396,372. The firm has a market capitalization of $26.99 billion, a P/E ratio of -70.51 and a beta of 1.12. The stock has a 50-day simple moving average of $34.16 and a 200-day simple moving average of $30.17. Roivant Sciences Ltd. has a 1-year low of $11.54 and a 1-year high of $37.46.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, sell-side analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently made changes to their positions in ROIV. Fifth Third Bancorp raised its stake in Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock worth $130,000 after acquiring an additional 376 shares in the last quarter. Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after acquiring an additional 441 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its position in shares of Roivant Sciences by 4.6% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after purchasing an additional 445 shares in the last quarter. Versant Capital Management Inc grew its stake in Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock valued at $141,000 after acquiring an additional 487 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its stake in Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock valued at $1,891,000 after purchasing an additional 500 shares in the last quarter. Institutional investors own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ROIV shares. HC Wainwright upped their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim boosted their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Piper Sandler restated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source